![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 18, 15523-15529, May 3, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,From the Department of Cell Physiology and Pharmacology, University of Leicester, University Road, Leicester, LE1 9HN, United Kingdom
Received for publication, November 26, 2001, and in revised form, January 25, 2002
| |
ABSTRACT |
|---|
|
|
|---|
We have previously shown that overexpression of G
protein-coupled receptor kinase 6 (GRK6) enhanced the phosphorylation
and desensitization of the endogenously expressed M3
muscarinic acetylcholine (mACh) receptor in human SH-SY5Y neuroblastoma
cells. In this study we have examined the potential role of endogenous
GRK6 in the regulation of M3 mACh receptor by blocking its
action through the introduction of a kinase-dead, dominant-negative
GRK6 (K215RGRK6). K215RGRK6 expression
inhibited methacholine-stimulated M3 mACh receptor phosphorylation by 50% compared with plasmid transfected control cells.
Guanosine-5'-O-(3-[35S]thio)triphosphate
binding and immunoprecipitation studies, conducted after agonist
pretreatment (3 min), indicated that M3 mACh
receptor-G The majority of G protein-coupled receptors desensitize
when stimulated continuously or repetitively. This process can be initiated via phosphorylation of the receptor, which leads to receptor-G protein uncoupling (1-3) and reduced receptor signaling to
downstream pathways. Second messenger-regulated kinases, such as
PKC1 (4) and
cAMP-dependent protein kinase (5, 6), and specific G
protein-coupled receptor kinases (GRKs) (7, 8) have been implicated in
G protein-coupled receptor desensitization through phosphorylation of
serine and threonine residues within the third intracellular loop or
C-terminal tail of G protein-coupled receptors. Upon agonist
stimulation, the human M3 muscarinic acetylcholine (mACh)
receptor is rapidly phosphorylated (9), and a number of different
kinases have been implicated in this process, including PKC (10, 11)
and casein kinase 1 More recently, we have examined the potential involvement of GRKs in
the desensitization of the M3 mACh receptor endogenously expressed in the SH-SY5Y cell line (13). This human neuroblastoma expresses GRKs 3 and 6, and overexpression of GRK3 and GRK6 leads to
enhanced M3 mACh receptor phosphorylation and reduced
activation of phospholipase C (PLC). However, only GRK6 overexpression
enhanced uncoupling of the receptor from G Although GRK6 overexpression can be shown to enhance the M3
mACh receptor desensitization process in SH-SY5Y cells, this
experimental approach is unable to resolve whether endogenous GRK6
contributes to M3 mACh receptor regulation. Therefore, in
an attempt to block the actions of endogenous GRK6, we have introduced
a kinase-dead, dominant-negative mutant form of GRK6, created by
introducing a K215R point mutation into the ATP-binding domain, into
SH-SY5Y cells to create cell lines stably expressing this construct.
Using this approach we have shown that K215RGRK6 expression
inhibits the phosphorylation and subsequent desensitization of the
M3 mACh receptor. Our data suggest that GRK6 plays a
significant role in the desensitization of the endogenously expressed
M3 mACh receptor in human SH-SY5Y neuroblastoma cells.
Cell Culture and Creation of Stably Transfected Dominant-negative
GRK Cell Lines--
SH-SY5Y human neuroblastoma cells were cultured in
minimal essential medium containing 5% fetal and 5% new born calf
serum, penicillin (100 units/ml), streptomycin (100 µg/ml), and
fungizone (2.5 µg/ml) (Invitrogen). All of the cells were maintained
at 37 °C in humidified conditions under 5% CO2.
Wild-type SH-SY5Y cells were transfected with either pcDNA3 alone
or human dominant-negative GRK5 or GRK6, both with a single point
mutation at K215R, cloned into pcDNA3 at BamHI and
XbaI, or EcoRI for GRKs 5 (14) and 6, respectively (both kindly provided by E. Kelly, University of Bristol,
Bristol, UK), using FuGENE 6 according to the manufacturer's instructions. After 48 h, geneticin (300 µg/ml) was added to the cells. The surviving colonies were selected and expanded into cell lines.
Western Blotting--
The cells were lysed and subjected to
electrophoretic separation exactly as described previously (15, 16).
The separated protein was transferred to nitrocellulose, and GRK
expression was detected using anti-rabbit polyclonal IgG antibodies
(1:1000 dilution) specific for GRK2, GRK3, GRK5, or GRK6 (Santa Cruz
Biotechnology). G Determination of mACh Receptor Number and Receptor
Internalization--
The Bmax and
Kd values were determined by
N-methyl-[3H]scopolamine
([3H]NMS; Amersham Biosciences) saturation binding
analysis of SH-SY5Y cell monolayers grown to confluence in 24-well
plates as described previously (13).
M3 mACh receptor internalization was assessed after
treatment with either vehicle or methacholine (100 µM)
for 0-60 min at 37 °C, prior to intensive washing (four times with
1 ml of ice-cold Krebs buffer, pH 7.4). [3H]NMS-binding
sites were determined as above using a single saturating concentration
(5 nM) of [3H]NMS for 18 h at 4 °C.
Nonspecific binding was determined by the addition of excess atropine
(20 µM). Receptor internalization was determined as the
percentage of loss of specific [3H]NMS-binding sites
after methacholine treatment when compared with vehicle-treated controls.
M3 mACh Receptor Phosphorylation--
The effect of
K215RGRK6 and K215RGRK5 expression on the
phosphorylation of endogenously expressed M3 muscarinic
receptors was assessed by the method of Tobin and Nahorski (9).
Briefly, either plasmid control or cells expressing either
K215RGRK6 or K215RGRK5 were seeded into 6-well
culture plates. Confluent cells were loaded with
[32P]orthophosphate (5 µCi/ml; Amersham Biosciences) in
phosphate-free Krebs buffer, pH 7.4, for 1 h prior to agonist
challenge (methacholine, 100 µM). After 3 min, the
agonist was removed, and the cells were solubilized,
immunoprecipitated, and electrophoretically resolved as described
previously (13). Autoradiograms were documented and quantified using
the GeneGenius system and software (Syngene, Cambridge, UK).
Casein Phosphorylation--
Any potential kinase activity of
dominant-negative GRK5 and GRK6 was assessed by measuring their ability
to phosphorylate the substrate Measurement of Total [3H]Inositol Phosphate
Accumulation--
Either plasmid control or cells expressing
K215RGRK5 or K215RGRK6 were seeded into 24-well
plates at ~50% confluency. After 24 h, the cells were incubated
in the presence of [3H]inositol (1 µCi/ml) in
geneticin-free medium for a further 24 h. Confluent cell
monolayers were then washed twice with Krebs buffer (118.6 mM NaCl, 4.7 mM KCl, 1.2 mM
MgSO4, 1.2 mM KH2PO4, 4.2 mM NaHCO3, 10 mM HEPES, 11.7 mM glucose, and 1.3 mM CaCl2, pH
7.4) and incubated for 15 min at 37 °C. LiCl (final concentration, 10 mM) was added to each well for 10 min prior to the
addition of methacholine. Reaction termination, sample neutralization, and separation of the [3H]inositol phosphate fraction
(containing inositol mono-, bis-, and tris-phosphates) were
performed as described previously (17).
Assessment of M3 mACh receptor G
[35S]GTP Data Analysis--
All concentration-response curves were
fitted, and the EC50 values were determined using nonlinear
regression analysis (GraphPad Prism 3). All data were analyzed using
one- or two-way analysis of variance (Microsoft Excel version 5).
Significance was accepted when p < 0.05.
Creation of Stable Dominant-negative GRK Cell
Lines--
Transfection of wild-type SH-SY5Y neuroblastoma cells with
either K215RGRK6 or K215RGRK5 and selection
with geneticin (300 µg/ml) yielded several surviving colonies, which
were expanded into cell lines. Two clones that expressed
K215RGRK6 and that were matched with plasmid controls for
receptor number based on [3H]NMS binding were selected
for further study (named D1 and D5; Fig.
1A). Estimation of the level
of K215RGRK6 expression was determined by serial dilution
of cell lysates and subsequent Western blotting, indicating ~30-fold
greater levels than endogenous GRK6 expression (data not shown). In an
attempt to examine the specificity of the effects of
K215RGRK6, a single clone expressing the closely related
K215RGRK5 (D2; Fig. 1B) was chosen for some
experiments. The level of overexpression of K215RGRK5 was
difficult to assess because there was no detectable endogenous GRK5 in
SH-SY5Y cells. To determine whether K215RGRK6 lacked kinase
activity (i.e. was kinase-dead), HEK293 cells were
transiently transfected with empty vector, GFP-tagged wt-GRK6, or
GFP-tagged K215RGRK6. After 48 h the kinases were
immunoprecipitated with either GFP polyclonal or wt-GRK6 antibodies.
Kinase activity was assessed by addition of dephosphorylated Effects of K215RGRK5 or K215RGRK6 on
Expression of Endogenous GRKs and CK1 Determination of M3 Receptor Number--
Whole cell
binding studies were undertaken using [3H]NMS to
determine whether expression of dominant-negative constructs affected M3 mACh receptor expression. The data obtained for
Bmax and KD indicated that expression of
either K215RGRK6 or K215RGRK5 had no
significant effect on M3 mACh receptor expression (Table
I). Moreover, receptor expression levels
did not alter with passage (data not shown).
M3 mACh Receptor Phosphorylation--
The effects of
K215RGRK6 expression on methacholine-stimulated (100 µM) M3 mACh receptor phosphorylation was
examined in clones D1 and D5. As shown in Fig.
3 (A and B), after
3 min of agonist exposure a robust phosphorylation was observed in the
plasmid control cell lines (P1 and P3). In contrast, M3
mACh receptor phosphorylation was reduced by ~50% in cells
expressing K215RGRK6. Furthermore, expression of
K215RGRK5 had no effect on agonist-stimulated
M3 mACh receptor phosphorylation (Fig. 3C).
Densitometric analysis confirmed that K215RGRK6 had no
effect on basal M3 mACh receptor phosphorylation. However,
K215RGRK6 significantly (p < 0.01) reduced
agonist-stimulated M3 mACh receptor phosphorylation by 50 and 43% for D1 compared with P3 and for D5 compared with P1 clones,
respectively (Fig. 4). Furthermore, expression of K215RGRK6 did not affect PKC-mediated
M3 mACh receptor phosphorylation stimulated by phorbol
12,13-dibutyrate (PDBu) (1 µM, 3 min; Fig. 3D).
Assessment of M3 mACh Receptor Desensitization by
[35S]GTP
First, we assessed whether expression of K215RGRK6 had any
effects on acute M3 mACh receptor-G Assessment of Phospholipase C Activity--
To further study the
effects of GRK6 on M3 mACh receptor regulation, we examined
the effects of K215RGRK6 on PLC activity using total
[3H]inositol phosphate accumulation. Time course studies
indicated that clones expressing K215RGRK6 produced
significantly (p < 0.01) greater
[3H]inositol phosphate accumulations than plasmid
controls matched for receptor number (Fig.
6, A and B). In
addition, concentration-response curves to MCh produced after 3 min
indicate that expression of K215RGRK6 enhanced
[3H]inositol phosphate accumulation when compared with
plasmid control cells (Fig. 7).
Interestingly, expression of the structurally similar dominant-negative
kinase K215RGRK5 had no effect on
[3H]inositol phosphate accumulation (Fig. 6C).
In addition, [3H]inositol phosphate accumulation was
similar in all clones after direct stimulation of G M3 mACh Receptor Internalization--
To assess
whether GRK6 mediated M3 mACh receptor internalization
plasmid control, GRK6-overexpressing (clone 24) or
K215RGRK6-expressing (D1) cells were exposed to MCh (100 µM) for up to 1 h. Subsequent [3H]NMS
binding revealed that overexpression of GRK6 had no effect on
M3 mACh receptor internalization. Furthermore, inhibition
of endogenous GRK6 with K215RGRK6 failed to inhibit
M3 mACh receptor internalization (Fig. 8).
We have recently shown that recombinant GRK6 can enhance both
M3 mACh receptor phosphorylation and
receptor/G Our data show for the first time the potential role of endogenous GRK6
in the regulation of an endogenously expressed
G The finding that certain GRKs can mediate inhibition of PLC activity
via nonreceptor phosphorylation mechanisms (23, 24) cautions against
the use of dominant-negative GRKs. However, the ability of GRK2 and
GRK3 to directly bind to activated, GTP-bound G Because GRK6 appears to regulate M3 mACh receptor
desensitization, it is interesting to speculate which phosphoacceptor
sites GRK6 may phosphorylate. Despite the wealth of studies implicating GRK involvement in receptor desensitization, no consensus sequence has
been agreed for GRK phosphorylation (3, 28, 29). Several studies have
identified serine or threonine clusters as favored targets for
GRK-mediated receptor phosphorylation (30, 31). Wu et al.
(32) have mapped the phosphorylation sites for GRK2 to two such regions
(331SSS333 and
348SASS351) in the third intracellular loop of
the M3 mACh receptor. Recent evidence examining the
phosphorylation profile of the B2 bradykinin receptor has
indicated that GRK (2, 3, 5 or 6) phosphorylation is limited to three
distinct serines situated in the C-terminal tail (33). Closer
examination of the individual serine moieties highlighted distinct
phosphorylation patterns between GRKs, raising the possibility that
different GRKs may regulate different receptor signaling mechanisms.
These data suggest that GRK6 and GRK2 M3 mACh receptor
phosphorylation sites may not be mutually exclusive but that
phosphorylation patterns may differ both temporally and positionally.
However, it is also noteworthy that unlike for the bradykinin
B2 receptor, determination of M3 mACh receptor
phosphorylation patterns is potentially much more complex because of
the presence of 36 serine and 16 threonine residues within the third
intracellular loop alone. Nevertheless, we have previously shown that
although GRK3 and GRK6 enhance M3 mACh receptor
phosphorylation, only GRK6 mediates uncoupling of the receptor from
G Many studies have reported that GRK overexpression not only leads to
enhanced desensitization but also accelerated internalization of
receptors (reviewed in Refs. 1 and 3). The present data indicate that
although GRK6 is capable of desensitizing the M3 mACh
receptor, it appears not to play a significant role in receptor internalization. This finding may appear surprising, but for some receptors kinase-mediated phosphorylation does not always enhance receptor internalization. Indeed, in agreement with our data, Lazari
et al. (21) found that although dominant-negative GRK2 or
GRK6 are equally capable of inhibiting follitropin receptor phosphorylation, only inhibition of GRK2-mediated phosphorylation prevents receptor internalization. Moreover, our data suggest that the
potential pattern of phosphoacceptor sites that mediate M3
mACh desensitization and internalization may be different. The presence
of GRK2, GRK3, CK1 In conclusion we have examined the potential role of endogenously
expressed GRK6 in the desensitization of M3 mACh receptors in the human SH-SY5Y cell line. Introduction of a dominant-negative, catalytically inactive GRK6 (K215RGRK6) inhibited both
agonist-stimulated M3 mACh receptor phosphorylation and
receptor/G
q/11 uncoupling was attenuated by 50% in
cells expressing K215RGRK6 when compared with control
cells. In contrast, expression of the related dominant-negative kinase
K215RGRK5 had no effect on M3 mACh receptor
phosphorylation or uncoupling. Time course studies also showed that
agonist-stimulated [3H]inositol phosphate accumulations
were more sustained in cells expressing K215RGRK6 compared
with control and K215RGRK5-expressing cells, whereas
K215RGRK6 expression had no effect on the phospholipase C
response to direct stimulation of G proteins with
AlF
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
(CK1
) (12). However, agonist-stimulated
receptor phosphorylation by either CK1
or PKC does not appear
to mediate rapid desensitization of the M3 mACh
receptor (10-12).
q/11 assessed
by a [35S]GTP
S binding/immunoprecipitation protocol.
In contrast, only GRK3 overexpression suppressed
AlF
q/11 and/or
free G
subunits, but highlight a potential role for GRK6 via
receptor phosphorylation and uncoupling of G
q/11.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
q/11 expression was detected using an
anti-rabbit polyclonal IgG (Santa Cruz Biotechnology). CK1
was
detected using an anti-rabbit polyclonal as described previously (12).
Protein expression was determined by the addition of ECL reagent
(Amersham Biosciences), according to the manufacturer's instructions
and exposure to Hyperfilm (Amersham Biosciences).
-casein as described previously
(13).
q/11
Coupling by [35S]GTP
S Binding--
Plasmid control or
dominant-negative GRK-expressing cells were grown in 80-cm2
cell culture flasks until confluent. The cells were then harvested in
10 mM HEPES, pH 7.4, 0.2% (v/v) EDTA, 0.9% (v/v) NaCl.
After centrifugation the cells were resuspended in Krebs buffer, pH 7.4, at 37 °C for 15 min prior to the addition of either vehicle or
MCh (100 µM). After 3 min, excess ice-cold Krebs buffer
(50 ml) was added, and the cells were pelleted at 1000 × g for 5 min. The cell pellets were then resuspended in 30 ml
of 20 mM HEPES, pH 7.4, 10 mM EDTA and
homogenized at maximum speed for 30 s using a PT210 Polytron. The
resulting suspension was centrifuged at 20,000 × g for
15 min. The pellet was resuspended in 30 ml of 20 mM HEPES,
pH 7.4, 0.1 mM EDTA and centrifuged for a further 15 min at
20,000 × g. The resulting pellet was resuspended at 1 mg/ml of protein and stored at
80 °C until required.
S binding and immunoprecipitation were
performed as described previously (18, 19). Briefly, 50 µg of
membranes were added to 1 nM [35S]GTP
S
(PerkinElmer Life Sciences), 1 µM GDP, 100 µM ±methacholine in assay buffer (100 mM
HEPES, 100 mM NaCl, 10 mM MgCl2, pH
7.4) and incubated for 2 min at 30 °C. Nonspecific binding was
determined by inclusion of 10 µM GTP
S. Termination,
solubilization, and G
q/11-specific immunoprecipitation
were performed exactly as described previously (13). Desensitization
was determined as a reduction in [35S]GTP
S binding
after pretreatment with methacholine and expressed as a percentage of
the response found when compared with a nonpretreated matched control.
In addition to desensitization experiments, M3 mACh
receptor activation of G
q/11 was assessed in
nonpretreated cell membranes via generation of methacholine (300 nM to 1 mM) concentration-response curves.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-casein
in the presence of [
-32P]ATP (as described under
"Experimental Procedures"). No phosphorylation of
-casein was
detected after transfection with empty vector, followed by
immunoprecipitation with GFP antibody (Fig. 1C). As expected, enhanced
-casein phosphorylation was detected after transfection of GFP-tagged GRK6. Furthermore, a slight phosphorylation of
-casein was detected after immunoprecipitation of endogenously expressed GRK6 from nontransfected HEK293 cells. In contrast,
-casein phosphorylation was not evident in the presence of
K215RGRK6.

View larger version (33K):
[in a new window]
Fig. 1.
Determination of expression and activity in
SH-SY5Y cells stably transfected with either K215RGRK6 or
K215RGRK5. Whole cell lysates were subjected to
SDS-PAGE followed by Western transfer and immunoblotting with
polyclonal antibodies recognizing either GRK6 (A) or GRK5
(B). In A and B, lysates were
corrected for protein with 40 µg loaded per lane. A,
lanes 1 and 3, clones P1 and P3 (plasmid
control), respectively; lanes 2 and 4, clones D5
and D1, respectively (K215RGRK6-expressing). B,
lane 1, clone P3 (plasmid control); lane 2, clone
D2 (K215RGRK5-expressing). C, assessment of GRK
function. HEK293 cells were transfected with empty vector (lanes
1 and 3), GFP-tagged GRK6 (lanes 2 and
5), or GFP-tagged K215RGRK6 (lanes 4 and 6). The cells were lysed and mixed with GFP polyclonal
antibody (lanes 1, 2, and 4-6) to
immunoprecipitate GFP-tagged kinases, before the addition of
[
-32P]ATP and dephosphorylated
-casein for 10 min
at 37 °C. GRKs were removed from the reaction mix by centrifugation,
and the resultant supernatant was separated by SDS-PAGE.
-Casein
phosphorylation was determined by autoradiography. Lane 3 shows the degree of
-casein phosphorylation seen after
immunoprecipitation of endogenous wt-GRK6, by wt-GRK6 polyclonal
antibody from HEK293 cells. The data are representative of three
separate experiments.
--
In an attempt to
determine whether overexpression of K215RGRK5 or
K215RGRK6 altered the expression of other endogenously
expressed kinases, we first blotted all the clones used in this study
for GRKs 2, 3, 5, and 6, as well as CK1
(Fig.
2). Overexpression of
K215RGRK5 had no effect on the expression of any of the
kinases studied. Furthermore, K215RGRK6 overexpression had
no effect on GRK2, GRK3, GRK5, or CK1
expression in any of the cell
lines. However, it was not possible to assess whether
K215RGRK6 altered the expression of endogenous GRK6 because
both K215RGRK6 and wild-type GRK6 are not distinguishable
with the antibody used (Fig. 2D).

View larger version (31K):
[in a new window]
Fig. 2.
Overexpression of K215RGRK5 or
K215RGRK6 does not effect the expression of endogenously
expressed GRKs or CK1
. Whole cell lysates
were subjected to SDS-PAGE followed by Western transfer and
immunoblotting with polyclonal antibodies recognizing either GRK2
(A), GRK3 (B), GRK5 (C), GRK6
(D), and CK1
(E) from P1 (lane 1),
P3 (lane 2), D1 (lane 3), D5 (lane 4),
and D2 (lane 5) cells. In all cases lysates were corrected
for protein with 40 µg loaded per lane. The data are representative
of three separate experiments.
Whole cell [3H]NMS saturation binding to determine M3
mACh receptor expression in plasmid control, K215RGRK6, and
K215RGRK5 expressing clones

View larger version (42K):
[in a new window]
Fig. 3.
Effects of K215RGRK6 expression
on agonist-stimulated M3 mACh receptor
phosphorylation. Confluent plasmid control and
K215RGRK6- or K215RGRK5-expressing cells were
loaded with [32P]orthophosphate (5 µCi/ml) in
phosphate-free Krebs buffer, pH 7.4. After 1 h cells were
challenged with MCh (100 µM) for 3 min, prior to lysis
and immunoprecipitation of the M3 mACh receptors with a
specific M3 mACh receptor antibody. The samples were
processed as described under "Experimental Procedures" and
corrected for receptor expression before quantification of
32P receptor incorporation by autoradiography.
Representative autoradiograms are shown for M3 mACh
receptor phosphorylation in P1 (lanes 1-3) and D5
(lanes 4-6) cells (A), and P3 (lanes
1-3) and D1 (lanes 4-6) cells (B), and P3
(lanes 1-3) and D2 (lanes 4-6) (C).
PKC-mediated M3 mACh receptor phosphorylation was also
examined in PDBu-treated P3 (lanes 1-3) and D1 (lanes
4-6) cells (D); lanes 1 and 3,
basals; lanes 2 and 5, PDBu (1 µM,
3 min); lanes 3 and 6, pretreatment with Ro
31-8220 (10 µM, 15 min) followed by PDBu (1 µM, 3 min).

View larger version (10K):
[in a new window]
Fig. 4.
Analysis of the effects of
K215RGRK6 expression on MCh-stimulated M3 mACh
receptor phosphorylation in two clones (D1 and D5). The samples
prepared as described under "Experimental Procedures" and in the
legend to Fig. 2 were subjected to densitometric analysis using the
GeneGenius image analysis system and software (Syngene). M3
mACh receptor phosphorylation is shown as basal (open bars)
and after methacholine (100 µM) stimulation (3 min,
black bars). The data are expressed as the means ± S.E. of four separate experiments. Expression of K215RGRK6
significantly inhibited methacholine-stimulated M3 mACh
receptor phosphorylation when compared with plasmid controls. *,
p < 0.01; **, p < 0.001.
S Binding--
To determine whether the
inhibition of agonist-stimulated M3 mACh receptor
phosphorylation observed with K215RGRK6 expression had a
subsequent effect on receptor function, we examined the direct
interaction of the M3 mACh receptor and G
q/11 at the point of receptor catalyzed GTP/GDP
exchange. Thus, we have used agonist-stimulated
[35S]GTP
S binding followed by immunoprecipitation of
G
q/11 in a membrane preparation (see "Experimental
Procedures").
q/11
interaction. Concentration-response curves in membranes from
nonpretreated K215RGRK6-expressing clones, undertaken at 2 min, the optimal time point for M3 mACh
receptor-G
q/11 activation (13, 19), showed binding
identical to that seen in controls (Fig.
5A). However, as described
previously (11, 13), pretreatment of intact cells with MCh (100 µM) for 3 min leads to reduced agonist-stimulated [35S]GTP
S binding to immunoprecipitated
G
q/11 in the subsequent membrane assay (Fig.
5B). Plasmid control cells (P1 and P3) showed 59 (D1
versus P3) and 46% (D5 versus P1) less
M3 mACh receptor-G
q/11 coupling when
compared with nonpretreated controls. In contrast, the degree of
receptor-G
q/11 uncoupling was inhibited by 50% with
K215RGRK6 expression (Fig. 5B). Interestingly,
despite agonist pretreatment, expression of K215RGRK5 had
no effect on M3 mACh receptor-G
q/11
uncoupling (Fig. 5B). These effects were not due to a loss
of membrane-associated G
q/11 because total
G
q/11 immunoreactivity in the membrane fraction was
unaltered after 3 min of pretreatment (Fig. 5C).

View larger version (19K):
[in a new window]
Fig. 5.
Effects of K215RGRK6 expression
on M3 mACh
receptor-G
q/11 coupling in SH-SY5Y
cells. A, Concentration-response curves for
methacholine-stimulated (300 nM to 1 mM)
M3 mACh receptor-G
q/11 recruitment in
plasmid control (P3,
) and cells expressing K215RGRK6
(D1,
; D5,
), as measured by [35S]GTP
S binding
and G
q/11 immunoprecipitation from nonpretreated cell
membranes. [35S]GTP
S binding was conducted at 30 °C
and at the peak of G
q/11 recruitment, 2 min. The data
are expressed as the means ± S.E. (in cpm) and are representative
of three separate experiments. Basal values were as follows: P3,
561 ± 86 cpm; D1, 554 ± 87 cpm; D5, 511 ± 81 cpm
(n = 3). B, effect of K215RGRK6
and K215RGRK5 (D2) expression on methacholine-stimulated
M3 mACh receptor uncoupling. Intact plasmid control (P1 and
P3), K215RGRK6 (D1 and D5), or
K215RGRK5-expressing cells were pretreated with
methacholine (100 µM) for 3 min at 37 °C. After
pretreatment, the cells were washed and converted into membranes, prior
to a second methacholine (100 µM) challenge, for 2 min at
30 °C, in the presence of [35S]GTP
S.
Methacholine-stimulated [35S]GTP
S binding to
G
q/11 after pretreatment was determined as described
under "Experimental Procedures," and the data were expressed as
fold over basal. M3 mACh receptor uncoupling was determined
as the decrease in [35S]GTP
S binding to
G
q/11 after methacholine pretreatment when compared with
the value obtained in a nonpretreated control (i.e. 0 = no uncoupling, whereas 100% = total receptor uncoupling). The data
shown are the means ± S.E. of three separate experiments.
K215RGRK6 expression significantly inhibited
methacholine-stimulated M3 mACh receptor uncoupling when
compared with plasmid control and K215RGRK5 overexpressing
cells. **, p < 0.001. Basal values were as follows:
P3, 812 ± 35 cpm; D1, 755 ± 90 cpm; D5, 602 ± 33 cpm;
D2, 805 ± 58 cpm (for six to eight separate experiments).
C, effects of methacholine (100 µM)
pretreatment on G
q/11 membrane association. The data
shown are a representative immunoblot indicating the levels of
membrane-bound G
q/11 in plasmid control (P3) or
K215RGRK6-expressing (D1) cells, either in the absence or
presence of MCh pretreatment. Lane 1, P3 cells, no
methacholine pretreatment; lane 2, MCh-pretreated P3 cells
(100 µM, 3 min, 37 °C); lane 3, D1 cells,
no MCh pretreatment; lane 4, MCh-pretreated D1 cells (100 µM, 3 min, 37 °C).
q/11
with AlF

View larger version (13K):
[in a new window]
Fig. 6.
Effects of dominant-negative GRK expression
on MCh (100 µM) stimulated
[3H]inositol phosphate accumulation in either.
A, P3 (plasmid control,
), D1
(K215RGRK6-expressing,
), or GRK6/24
(GRK6-overexpressing,
) cells; B, P1 (plasmid control,
) or D5 (K215RGRK6-expressing,
) cells; C,
P3 (plasmid control,
) or D2 (K215RGRK5-expressing,
)
cells. [3H]Inositol phosphate accumulation was determined
as described under "Experimental Procedures." The data are
expressed as the means ± S.E. for three to five independent
experiments. [3H]Inositol phosphate accumulation was
significantly (p < 0.01, by two-way analysis of
variance) increased in cells expressing K215RGRK6 when
compared with plasmid control and K215RGRK5-expressing
cells.

View larger version (17K):
[in a new window]
Fig. 7.
Methacholine concentration-response curves in
plasmid control or cells expressing either K215RGRK6 or
GRK6. [3H]Inositol phosphate accumulation was
determined as described under "Experimental Procedures." The data
are expressed as the means ± S.E. for three separate experiments.
A shows P3 (plasmid control,
), D1
(K215RGRK6-expressing,
), and GRK6 clone 24 (GRK6
overexpressing,
) cells. Similar data were obtained for P1 and D5
cells. [3H]Inositol phosphate accumulation was
significantly (p < 0.01) greater and significantly
reduced (p < 0.01) in cells that expressed
K215RGRK6 or GRK6, respectively, compared with plasmid
control cells.

View larger version (15K):
[in a new window]
Fig. 8.
Assessment of MCh-stimulated M3
mACh receptor internalization in plasmid control (P3,
),
wt-GRK6-overexpressing (clone 24,
), or
K215RGRK6-expressing (clone D1,
) cells. The cells
were treated with either vehicle or MCh (100 µM) for
0-60 min, prior to extensive washing and subsequent
[3H]NMS binding (5 nM) for 18 h at
4 °C. Nonspecific binding was determined in the presence of atropine
(20 µM). Receptor internalization was determined as the
percentage of loss of [3H]NMS-binding sites after MCh
treatment when compared with vehicle-treated controls. The data are
expressed as the means ± S.E. for three separate
experiments.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
q/11 uncoupling, subsequently increasing
desensitization of the endogenously expressed M3 mACh
receptor in the SH-SY5Y neuroblastoma cell line (13). These data are
suggestive of a role for endogenous GRK6 in the regulation of
M3 mACh receptor desensitization. Therefore, in an attempt
to block the action of endogenously expressed GRK6 in SH-SY5Y cells, we
have introduced a kinase-dead, dominant-negative mutant,
K215RGRK6.
q/11-coupled receptor. Despite the many studies
indicating that GRKs are able to enhance the phosphorylation of
overexpressed receptors (reviewed in Ref. 1), relatively few have
examined the role of endogenous GRK6 activity in the regulation of
endogenously expressed receptors. Introduction of antisense GRK6
oligonucleotides inhibited desensitization of the calcitonin
gene-related peptide receptor stably expressed in HEK293 cells (20).
However, several recent studies have reported the use of differing
versions of dominant-negative GRK6 and have provided conflicting
evidence as to their effectiveness in inhibiting endogenous GRK6.
Lazari et al. (21) were able to inhibit endogenous GRK6
phosphorylation of follitrophin receptors in HEK293 cells by
introducing a double point-mutated GRK6 (K215M/K216M). Zhou et
al. (22) introduced a triple point-mutated (R215K/D484S/D485S) dominant-negative GRK6 that reduced agonist-stimulated thomboxane A2 receptor phosphorylation when compared with equivalent
overexpression of GRK6 (22). However, unlike the present data, where we
show a 50% reduction in agonist-stimulated M3 mACh
receptor phosphorylation with expression of K215RGRK6, the
action of endogenous GRK6 appeared not to be inhibited by this
dominant-negative (R215K/D484S/D485SGRK6) (22). In view of
these findings we chose to determine the catalytic activity of our
dominant-negative GRK6 using immunoprecipitation of GFP-tagged GRK6 or
K215RGRK6 and
-casein as substrate. These studies
indicated that unlike wt-GRK6, K215RGRK6 was devoid of
-casein phosphorylating activity.
q/11 via
their N-terminal RGS domain is not seen with GRK5 and GRK6 (23, 24). In
addition, direct stimulation of PLC via activation of G proteins using
AlF
-casein (data not shown). However, if the
M3 mACh receptor was able to recruit GRK5, one might expect K215RGRK5 to block access of similar kinases to the
receptor after agonist stimulation. The absence of this finding,
combined with the inhibition of M3 mACh receptor
phosphorylation by K215RGRK6, suggests that the recruitment
signals for GRK5 or GRK6 are likely to be different even for these
closely related kinases. It is also of interest that phosphorylation of
the M3 mACh receptor by direct stimulation of PKC (by PDBu)
was unaltered by the expression of K215RGRK6. All of these
data imply that K215RGRK6-mediated inhibition of
M3 mACh phosphorylation is not due to a nonspecific
physical association of receptor and kinase but requires the specific
recruitment of GRK6 by the receptor after agonist activation.
q/11 (13). Furthermore, inhibition of endogenous GRK6
with a 30-fold excess of K215RGRK6 only produced a 50%
decrease in M3 receptor phosphorylation and
G
q/11 uncoupling. This finding could suggest either that increasing K215RGRK6 overexpression may further inhibit
M3 mACh receptor phosphorylation and G
q/11
uncoupling or more likely that other kinases such as GRK2 or 3 may
contribute to M3 mACh receptor desensitization in SH-SY5Y cells.
, and PKCs in SH-SY5Y cells and their ability to
phosphorylate the M3 mACh receptor (10-13, 32) raise the
possibility that one or more of these kinases may be responsible for
regulating M3 mACh receptor internalization. Indeed, recent
preliminary studies have shown that dominant-negative CK1
inhibits
M1 receptor internalization when concurrently overexpressed in HEK293 cells (34). Furthermore, we have shown that overexpression of
GRK3 in SH-SY5Y cells (13), and others have reported that GRK2 in
Chinese hamster ovary cells (35) enhanced M3 mACh receptor internalization. It will be interesting to examine which of these kinases plays a role in the internalization of the endogenously expressed M3 mACh receptor in SH-SY5Y cells and whether
this is crucial for recruitment of adaptor proteins and initiating
alternative signaling cascades.
q/11 uncoupling. Furthermore,
K215RGRK6 expression partially reversed the time-related
decay of agonist activation of PLC. In contrast, the closely related
K215RGRK5 was unable to affect M3 mACh
signaling in any way. Despite the obvious effects of GRK6 on
M3 mACh receptor PLC-coupled signaling, manipulation of
GRK6 activity had no effect on receptor internalization. Overall these
data suggest that endogenous GRK6 regulates, at least in part,
M3 mACh receptor desensitization in human SH-SY5Y neuroblastoma cells.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Dr. Eamonn Kelly (Department of Pharmacology, University of Bristol, Bristol, UK) for kindly donating the K215RGRK5 and K215RGRK6 constructs. We gratefully acknowledge the contribution of Dr. J. Parkinson, who made the GFP-tagged GRK6 and K215RGRK6 constructs.
| |
FOOTNOTES |
|---|
* This work was supported by Wellcome Trust Grant 062495.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Cell
Physiology and Pharmacology, University of Leicester, Maurice Shock Medical Sciences Bldg., University Rd., Leicester, LE1 9HN, UK. Tel.: 0116-252-3075; Fax: 0116-252-5045; E-mail:
jmw23@le.ac.uk.
Published, JBC Papers in Press, February 20, 2002, DOI 10.1074/jbc.M111217200
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
PKC, protein kinase
C;
GRK, G protein-coupled receptor kinase;
mACh, muscarinic
acetylcholine;
MCh, methacholine;
PLC, phospholipase C;
PDBu, phorbol
12,13-dibutyrate;
NMS, N-methylscopolamine;
CK1
, casein
kinase 1
;
GTP
S, guanosine 5'-3-O-(thio)triphosphate;
GFP, green fluorescent protein.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Bunemann, M.,
and Hosey, M. M.
(1999)
J. Physiol.
517,
5-23 |
| 2. |
Sterne-Marr, R.,
and Benovic, J. L.
(1996)
Vitam. Horm.
51,
193-234 |
| 3. |
Ferguson, S. S. G.
(2001)
Pharmacol. Rev.
53,
1-24 |
| 4. |
Pitcher, J. A.,
Lohse, M.,
Codina, J.,
Caron, M. G.,
and Lefkowitz, R. J.
(1992)
Biochemistry
31,
3193-3197[CrossRef][Medline]
[Order article via Infotrieve] |
| 5. |
Benovic, J. L.,
Pike, L. J.,
Cerione, R. A.,
Staniszewski, C.,
Yoshimasa, T.,
Codina, J.,
Caron, M. G.,
and Lefkowitz, R. J.
(1985)
J. Biol. Chem.
260,
7094-7101 |
| 6. |
Clark, R. B.,
Friedman, J.,
Dixon, R. A. F.,
and Strader, C. D.
(1989)
Mol. Pharmacol.
36,
343-348[Abstract] |
| 7. |
Krupnick, J. G.,
and Benovic, J. L.
(1998)
Ann. Rev. Pharmacol. Toxicol.
38,
289-319[CrossRef][Medline]
[Order article via Infotrieve] |
| 8. |
Pitcher, J. A.,
Freedman, N. J.,
and Lefkowitz, R. J.
(1998)
Ann. Rev. Biochem.
67,
653-692[CrossRef][Medline]
[Order article via Infotrieve] |
| 9. |
Tobin, A. B.,
and Nahorski, S. R.
(1993)
J. Biol. Chem.
268,
9817-9823 |
| 10. |
Willars, G. B.,
Muller-Esterl, W.,
and Nahorski, S. R.
(1999)
Am. J. Physiol.
277,
C859-C869[Medline]
[Order article via Infotrieve] |
| 11. |
Bundey, R. A.,
and Nahorski, S. R.
(2001)
Br. J. Pharmacol.
134,
257-264[CrossRef][Medline]
[Order article via Infotrieve] |
| 12. |
Budd, D. C.,
McDonald, J. E.,
and Tobin, A. B.
(2000)
J. Biol. Chem.
275,
19667-19675 |
| 13. |
Willets, J. M.,
Challiss, R. A. J.,
Kelly, E.,
and Nahorski, S. R.
(2001)
Mol. Pharmacol.
60,
321-330 |
| 14. |
Tiruppathi, C.,
Yan, W.,
Sandoval, R.,
Naqvi, T.,
Pronin, A. N.,
Benovic, J. L.,
and Malik, A. B.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
7440-7445 |
| 15. |
Mundell, S. J.,
Luty, J. S.,
Willets, J. M.,
Benovic, J. L.,
and Kelly, E.
(1998)
Br. J. Pharmacol.
125,
347-356[CrossRef][Medline]
[Order article via Infotrieve] |
| 16. |
Willets, J. M.,
and Kelly, E.
(2001)
Eur. J. Pharmacol.
431,
133-141[CrossRef][Medline]
[Order article via Infotrieve] |
| 17. | Challiss, R. A. J., Jenkinson, S., Mistry, R., Batty, I. H., and Nahorski, S. R. (1993) Neuroprotocols 3, 135-144 |
| 18. |
Barr, A. J.,
Brass, L. F.,
and Manning, D. R.
(1998)
J. Biol. Chem.
272,
2223-2229 |
| 19. |
Akam, E. C.,
Challiss, R. A. J.,
and Nahorski, S. R.
(2001)
Br. J. Pharmacol.
132,
950-958[CrossRef][Medline]
[Order article via Infotrieve] |
| 20. |
Aiyar, N.,
Disa, J.,
Dang, K.,
Pronin, A. N.,
Benovic, J. L.,
and Nambi, P.
(2000)
Eur. J. Pharmacol.
403,
1-7[CrossRef][Medline]
[Order article via Infotrieve] |
| 21. |
Lazari, M.,
Liu, X.,
Nakamura, K.,
Benovic, J. L.,
and Ascoli, M.
(1999)
Mol. Endocrinol.
13,
866-878 |
| 22. |
Zhou, H.,
Yan, F.,
and Tai, H.-H.
(2001)
J. Pharmacol. Exp. Ther.
298,
1243-1251 |
| 23. |
Carman, C. V.,
Parent, J.-L.,
Day, P. W.,
Pronin, A. N.,
Sternweis, P. M.,
Wedergaertner, P. B.,
Gilman, A. G.,
Benovic, J. L.,
and Kozasa, T.
(1999)
J. Biol. Chem.
274,
34483-34492 |
| 24. |
Sallese, M.,
Mariggio, S.,
D'Urbano, E.,
Iacovelli, L.,
and De Blasi, A.
(2000)
Mol. Pharmacol.
57,
826-831 |
| 25. |
Pronin, A. N.,
Satpaev, D. K.,
Slepak, V. Z.,
and Benovic, J. L.
(1997)
J. Biol. Chem.
272,
18273-18280 |
| 26. |
Pitcher, J. A.,
Fredericks, Z. L.,
Stone, W. C.,
Premont, R. T.,
Stoffel, R. H.,
Koch, W. J.,
and Lefkowitz, R. J.
(1996)
J. Biol. Chem.
271,
24907-24913 |
| 27. |
Gainetdinov, R. R.,
Bohn, L. M.,
Walker, J. K.,
Laporte, S. A.,
Macrae, A. D.,
Caron, M. G.,
Lefkowitz, R. J.,
and Premont, R. T.
(1999)
Neuron
24,
1029-1036[CrossRef][Medline]
[Order article via Infotrieve] |
| 28. |
Fredericks, Z. L.,
Pitcher, J. A.,
and Lefkowitz, R. J.
(1996)
J. Biol. Chem.
271,
13796-13803 |
| 29. |
Seibold, A.,
January, B. G.,
Freidman, J.,
Hipkin, R. W.,
and Clark, R. B.
(1998)
J. Biol. Chem.
273,
7637-7642 |
| 30. |
Pals-Rylaarsdam, R.,
and Hosey, M. M.
(1997)
J. Biol. Chem.
272,
14152-14158 |
| 31. |
Maestes, D. C.,
Potter, R. M.,
and Prossnitz, E. R.
(1999)
J. Biol. Chem.
274,
29791-29795 |
| 32. |
Wu, G.,
Bogatkevich, G. S.,
Mukhin, Y. V.,
Benovic, J. L.,
Hildebrandt, J. D.,
and Lanier, S. M.
(2000)
J. Biol. Chem.
275,
9026-9034 |
| 33. |
Blaukat, A.,
Pizard, A.,
Breit, A.,
Wernstedt, C.,
Alhenec-Gelas, F.,
Muller-Esterl, W.,
and Dikic, I.
(2001)
J. Biol. Chem.
276,
40431-40440 |
| 34. |
Kellerbauer, A.,
Krudewig, R.,
Langer, B.,
Jakobs, K. H.,
and van Koppen, C. J.
(2001)
Naunyn-Schmiedeberg's Arch. Pharmacol.
363 (suppl.),
72 |
| 35. |
Tsuga, H.,
Okuno, E.,
Kameyama, K.,
and Haga, T.
(1998)
J. Pharmacol. Exp. Ther.
284,
1218-1226 |
This article has been cited by other articles:
![]() |
J. Luo, J. M. Busillo, and J. L. Benovic M3 Muscarinic Acetylcholine Receptor-Mediated Signaling Is Regulated by Distinct Mechanisms Mol. Pharmacol., August 1, 2008; 74(2): 338 - 347. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Braverman, A. S. Tibb, and M. R. Ruggieri Sr M2 and M3 Muscarinic Receptor Activation of Urinary Bladder Contractile Signal Transduction. I. Normal Rat Bladder J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 869 - 874. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Dabisch, D. B. Miller, S. A. Reutter, R. J. Mioduszewski, and S. A. Thomson Miotic Tolerance to Sarin Vapor Exposure: Role of the Sympathetic and Parasympathetic Nervous Systems Toxicol. Sci., June 1, 2005; 85(2): 1041 - 1047. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-R. Ren, E. Reiter, S. Ahn, J. Kim, W. Chen, and R. J. Lefkowitz Different G protein-coupled receptor kinases govern G protein and {beta}-arrestin-mediated signaling of V2 vasopressin receptor PNAS, February 1, 2005; 102(5): 1448 - 1453. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Popova and M. M. Rasenick Clathrin-mediated Endocytosis of m3 Muscarinic Receptors: ROLES FOR G{beta} |